Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Bio-Rad is a multinational manufacturer and distributor of life science research and clinical diagnostics products. The company operates through two primary segments: Life Science and Clinical Diagnostics. Approximately 69% of net sales are generated from international locations.
Key Financial Metrics
| Metric (in thousands) | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $454,234 | $400,933 |
| Gross Profit | $257,127 | $228,902 |
| Gross Margin | 56.6% | 57.1% |
| Income from Operations | $63,247 | $51,437 |
| Net Income (Attributable to Bio-Rad) | $34,861 | $30,265 |
| Diluted EPS | $1.24 | $1.10 |
| Cash from Operating Activities | $22,269 | $6,371 |
| Cash and Cash Equivalents (End of Period) | $598,134 | $192,870 |
| Total Debt (Long-term + Current) | $743,766 | N/A |
Note: Total debt calculated as Long-term debt ($738,662) plus current maturities ($5,104) from the Balance Sheet.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.3% year-over-year to $454.2 million. This includes approximately $12.7 million in sales from the acquisition of certain diagnostic businesses of Biotest AG. Excluding foreign currency impacts, sales grew 7.9%.
- Segment Performance:
- Life Science: Sales increased 7.9% to $151.4 million; gross margins improved by 1.6% due to better manufacturing overhead absorption.
- Clinical Diagnostics: Sales increased 16.4% to $299.8 million. Gross margins decreased by 1.5%, partially due to the lower-margin Biotest acquisition and purchase accounting adjustments.
- Expenses: Interest expense increased by $6.6 million to $14.4 million, driven by the issuance of $300 million in 8.0% Senior Subordinated Notes in May 2009. SG&A expenses as a percentage of sales decreased to 33.8% from 35.0%.
- Tax Rate: The effective tax rate increased to 29% from 26%, primarily due to the expiration of the U.S. research and development tax credit and an increase in liabilities for uncertain tax positions.
Outlook, Risks, and Unusual Items
- Acquisition: On January 6, 2010, Bio-Rad acquired diagnostic businesses from Biotest AG for approximately $64.9 million in cash. This is expected to broaden the immunohematology product offering.
- Legal Proceedings (FCPA): In May 2010, the company disclosed an internal review identifying conduct in overseas operations that may have violated the anti-bribery provisions of the U.S. Foreign Corrupt Practices Act (FCPA). The company voluntarily disclosed these matters to the DOJ and SEC. An independent investigation is underway. Potential sanctions could include fines, disgorgement, and compliance monitors, which may have a material adverse effect on the business.
- Liquidity: The company had $691.8 million in cash, cash equivalents, and short-term investments as of March 31, 2010. A $200 million Revolving Credit Facility expires on June 21, 2010, and the company is evaluating renewal options.
- Market Risks: The company faces risks related to global economic conditions, currency exchange rate fluctuations (69% of sales are international), and the ability to successfully integrate acquired businesses.
Investor Verification Checklist
- FCPA Investigation Status: Monitor updates regarding the scope, findings, and potential penalties related to the Foreign Corrupt Practices Act investigation disclosed in May 2010.
- Debt Covenants: Verify continued compliance with financial covenants (leverage ratio, interest coverage) given the substantial debt load of approximately $743 million.
- Acquisition Integration: Assess the financial performance and integration progress of the Biotest AG acquisition in subsequent quarters.
- Credit Facility Renewal: Confirm the renewal or replacement of the $200 million Revolving Credit Facility expiring in June 2010.
- Tax Liability: Track the resolution of uncertain tax positions which contributed to the increased effective tax rate in Q1 2010.